Microbiota Restoration for Reduction of Recurrent C. difficile Infection - Understanding the Human Gut Microbiota

Released On
November 14, 2019

Expires On
November 14, 2020

Media Type

Completion Time
60 minutes

Gastroenterology, Hospitalist, Infectious Disease, Pharmacy

Scroll to the Bottom of this Information to Begin this Course


Supported by an educational grant from Ferring Pharmaceuticals, Inc

Credit Available

  • Physicians — maximum of 1 AMA PRA Category 1 Credit(s)
  • Pharmacists — maximum of 1 CPE contact hour

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for ID specialists, hospitalists, internists, physicians, pharmacists and other clinicians who care for patients at risk of serious infection.

Statement of Need/Program Overview

Faculty will review unmet clinical needs in the context of available therapies and guidelines for reducing recurrent C. difficile. The role of the gut microbiome in C. difficile infection and emerging approaches to restoration as a means to break the cycle of recurrent C. difficile will also be discussed.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
  • Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
  • Restate guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
  • Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy



Associate Professor of Medicine, Division of Infectious Diseases
Corporate Medical Director, Infection Prevention, Epidemiology, and Antibiotic Stewardship
Wayne State University
Detroit Medical Center
Director, Infection Prevention, Epidemiology and Antibiotic Stewardship
Vibra Hospital
Detroit, MI

Paul Feuerstadt, MD, FACG, AGAF

Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT

Sahil Khanna, MBBS, MS

Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

This activity has been approved for 1.0 contact hour.

ACPE Universal Activity Number: 0396-0000-19-080-H01-P
Activity Type(s): Knowledge

Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CPE activity.

The following financial relationships have been provided:

Teena Chopra, MD, MPH

  • Speakers Bureau: Allergan, Cepheid, Melinta Therapeutics, Inc., Merck & Company, Pfizer
  • Consulting Agreements: Cepheid, Shionogi, Inc.
  • Data and Safety Monitoring Board Chari (DSMB): Ferring Pharmaceuticals, Inc.

Paul Feuerstadt, MD, FACG, AGAF

  • Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
  • Speakers' Bureau: Merck and Company

Sahil Khanna, MBBS, MS

  • Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
  • Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes

Instructions for Participation and Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 70% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Partial credit may not be awarded for pharmacy credit; participation in the complete activity is required to receive credit.

For questions, contact Melissa Stradal at 773-714-0705 x160

CPE credit will be submitted to CPE Monitor® on the first day of each month.

Course Viewing Requirements

  1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
  2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
  3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
  4. Adobe Flash Player 12.0 (or higher).
  5. Adobe Reader to print certificate.
  6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.

Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CPE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Program Agenda

Welcome & Introductions
The Changing Epidemiology and Treatment of C. difficile – Dr. Paul Feuerstadt
Role of the Gut Microbiome – Dr. Teena Chopra
Breaking the Cycle of Recurrence – Dr. Sahil Khanna